Paul B. Chapman
Cornell University · 495 works · 44,066 citations · h-index 75
Top works
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
- Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
- RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
- Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
- The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner
- Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
- Phase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer
- Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysis
- Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer.
- Evolutionary dynamics of cancer in response to targeted combination therapy
- AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: An open-label, randomized, multicenter, phase II study
- Selective CD4+ Lymphopenia in Melanoma Patients Treated With Temozolomide: A Toxicity With Therapeutic Implications